Advertisement

KEYNOTE-522: Event-Free Survival With Neoadjuvant and Adjuvant Pembrolizumab for Triple-Negative Breast Cancer
Posted: 02/28/2022 | By: Matthew Stenger

Question 1 of 5

The hazard ratio for event-free survival for the pembrolizumab group vs control group in the total population was:

Choose 1

A
0.63
B
0.78
C
0.65
D
0.73

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage